Platelet-active drugs : the relationships among dose, effectiveness, and side effects.

Abbreviations: ACE trial 5 Acetylsalicylic Acid and Carotid Endarterectomy; ADP 5 adenosine diphosphate; AMP 5 adenosine monophosphate; CAPRIE study 5 Clopidogrel vs Aspirin in Patients at Risk of Ischemic Events; CI 5 confidence interval; COX 5 cyclooxygenase; DVT 5 deep venous thrombosis; EPISTENT trial 5 Evaluation of Platelet IIb/IIIa Inhibitors for Stenting; ESPS 5 European Stroke Prevention Study; EXCITE trial 5 Evaluation of Xemilofiban in Controlling Thrombotic Events; FDA 5 Food and Drug Administration; GP 5 glycoprotein; HOT study 5 Hypertension Optimal Treatment; INR 5 international normalized ratio; LMWH 5 low-molecular-weight heparin; MI 5 myocardial infarction; NSAID 5 nonsteroidal antiinflammatory drug; OPUS trial 5 Orbofiban in Patients with Unstable Coronary Syndromes; PCI 5 percutaneous coronary intervention; PE 5 pulmonary embolism; PEP trial 5 Pulmonary Embolism Prevention; PG 5 prostaglandin; PTCA 5 percutaneous transluminal coronary angioplasty; RGD 5 Arg-Gly-Asp sequence; RR 5 relative risk; TIA 5 transient ischemic attack; TPT 5 Thrombosis Prevention Trial; TTP 5 thrombocytopenic purpura; TX 5 thromboxane; VTE 5 venous thromboembolism (CHEST 2001; 119:39S–63S)